Treatment of lymphoblastic leukemia in children with Down syndrome
https://doi.org/10.21508/1027-4065-2021-66-2-105-109
Abstract
Acute leukemia accounts for 30% of malignant neoplasms in children in Russia. Down’s syndrome (trisomy of chromosome 21) is considered one of the strongest predictors of acute leukemia. Genetic abnormalities in patients with Down syndrome are strategically important for treatment approaches, metabolism of certain drugs, and sensitivity of blast cells to chemotherapy.
The article describes three clinical cases of patients with acute lymphoblastic leukemia with Down’s syndrome who developed severe complications requiring correction of the dosage of chemotherapy.
This cohort of patients is at high risk for the development of hematological, metabolic and infectious complications that require individualization of regimens and dosage of chemotherapy drugs.
About the Authors
A. S. Ulanova
Vyzhletsov Аrkhangelsk Regional Children’s Clinical Hospital; Northern State Medical University, Аrkhangelsk
Russian Federation
Russian Federation
Аrkhangelsk
N. A. Grigoryeva
Vyzhletsov Аrkhangelsk Regional Children’s Clinical Hospital; Northern State Medical University, Аrkhangelsk
Russian Federation
Russian Federation
Аrkhangelsk
I. A. Turabov
Northern State Medical University
Russian Federation
Russian Federation
Аrkhangelsk
Ia. S. Oleynik
Northern State Medical University
Russian Federation
Russian Federation
Аrkhangelsk
M. Yu. Rykov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Moscow
References
1. Злокачественные новообразования в России (заболеваемость и смертность) в 2018 году. Под ред. А.Д. Ка- прина, В.В. Старинского, Г.В. Петровой. М.: Московский научно-исследовательский онкологический институт им. П.А. Герцена Минздрава России, 2019; 250. [Malignancies in Russ.ia (morbidity and mortality) in 2018. A.D. Kaprin, V.V. Starinsky, G.V. Petrova (eds). Moscow: P.A. Herzen Moscow research oncological Institute of the Ministry of health of the Russian Federation, 2019; 250. (in Russ.)]
2. Рыков М.Ю., Байбарина Е.Н., Чумакова О.В., Поляков В.Г. Эпидемиология злокачественных новообразований у детей в Российской Федерации: анализ основных показателей и пути преодоления дефектов статистических данных. Онкопедиатрия 2017; 4(3): 159–177. [Rykov M.Yu., Baibarina E.N., Chumakova O.V., Polyakov V.G. Cancer epidemiology in children in the Russian Federation: analysis of key indicators and ways to overcome the statistical data defects. Onkopediatriya (Oncopediatrics) 2017; 4(3): 159–177. (In Russ.)] DOI: 10.15690/onco.v4i3.1747
3. Турабов И.А. Онкологическая заболеваемость детского населения на европейском севере России. Детская онкология 2003; 4: 29–36. [Turabov I.A. Oncological morbidity of children’s population in the European North of Russia. Detskaya onkologiya (Children’s Oncology) 2003; 4: 29–36. (in Russ.)]
4. Турабов И.А., Кудрявцев В.А., Кустышев И.Г., Денщиков Б.В. Онкологическая заболеваемость детей европейского Севере России (распространенность, структура). Экология человека 1999; 2: 61–64. [Turabov I.A., Kudryavtsev V.A., Kustyshev I.G., Denshchikov B.V. Oncological morbidity of children in the North of Russia (prevalence, structure). Ekologiya cheloveka 1999; 2: 61–64. (in Russ.)]
5. Турабов И.А., Кудрявцев А.В., Рыков М.Ю., Карпунов А.А., Уланова А.С. Онкологическая заболеваемость детей в Архангельской области и Ненецком автономном округе: экологическое исследование. Онкопедиатрия 2019; 6(2): 70–77. [Turabov I.A., Kudryavtsev A.V., Rykov M.Yu., Karpunov A.A., Ulanova A.S. Oncological morbidity of children in the Arkhangelsk region and the Nenets Autonomous district: an ecological study. Onkopediatriya (Oncopediatrics) 2019; 6(2): 70–77. (in Russ.)]
6. Boker K., Blumstein T., Sadetzki S., Luxenburg O., Litvak I., Akstein E., Modan B. Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int J Cancer 2001; 93: 741–744
7. Chisholm K.M. Acute lymphoblastic leukemia in Down syndrome. Atlas Genet Cytogenet Oncol Haematol 2018; 22(8): 341–345. DOI: 10.1017/CBO9780511977633.014
8. Xavier А.С., Jeffrey W.Т. Acute leukemia in children with Down syndrome. Haematol 2010; 95: 1043–1045. DOI: 10.3324/haematol.2010.024968
9. Jumana A.Y., Muhammad A.S., Sultan A., Zoheir A. Altered Metabolism in Down Syndrome. Health Problems in Down Syndrome 2015; 4: 1–25. DOI: 10.5772/60638
10. Izraeli S., Vora A., Zwaan C., Whitlock J. How I treat ALL in Down’s syndrome: pathobiology and management. Blood 2014; 123(1): 35–40. DOI: 10.1182/blood-2013-07-453480
11. Pui C.-H. Childhood Leukemias. Cambridge: University Press, 1999; 18. DOI: 10.1017/CBO9780511471001.019
12. Lennard L., Cartwright C.S., Wade R., Vora A. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol 2015; 170(5): 550–558. DOI: 10.1111/bjh.13469
13. Schmiegelow К., Nielsen S.N., Frandsen T.L., Nersting J. Mer- captopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction. J Pediatr Hematol Oncol 2014; 36: 503–517. DOI: 10.1097/mph.0000000000000206
14. Ravindranath Y., Ginopolis G. Down Syndrome and Leu- kemia: New Insights Into the Epidemiology, Pathogenesis, and Treatment. Pediatr Blood Cancer 2005; 44: 1–7. DOI: 10.1002/pbc.20242
Review
For citations:
Ulanova A.S., Grigoryeva N.A., Turabov I.A., Oleynik I.S., Rykov M.Yu. Treatment of lymphoblastic leukemia in children with Down syndrome. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(2):105-109. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-2-105-109
Views:
650
Email this article 